Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21Cip1/WAF1 and p27Kip1

Cellular Oncology

Volumn 36, Issue 1, 2013, Pages 79-93

  Wei, Min ^a   Liu, Bingya ^a   Gu, Qinlong ^a   Su, Liping ^a   Yu, Yingyan ^a   Zhu, Zhenggang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Breast cancer; p21; p27; Stat6

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; GLUTATHIONE TRANSFERASE; LUCIFERASE; MESSENGER RNA; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN; RIBONUCLEASE; STAT6 PROTEIN; THYMIDINE; TRANSCRIPTION FACTOR SP1;

ARTICLE; BINDING SITE; BREAST CANCER; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SYNCHRONIZATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; S PHASE; SP1 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR;

EID: 84877012000     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-012-0115-3     Document Type: Article

References (70)

1. J. Hasty, D. McMillen, J.J. Collins, Engineered gene circuits. Nature 420, 224-230 (2002)
2. Q. Wang, Y. Zhou, X. Wang, B.M. Evers, p27Kip1 nuclear localization and cyclin-dependent kinase inhibitory activity are regulated by glycogen synthase kinase-3 in human colon cancer cells. Cell Death Differ 15, 908-919 (2008)
3. I. Soerjomataram, M.W. Louwman, J.G. Ribot, J.A. Roukema, J.W. Coebergh, An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107, 309-330 (2008)
4. C.E. Caldon, C.S. Lee, R.L. Sutherland, E.A. Musgrove, Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation. Oncogene 27, 126-138 (2008)
5. S. Sheahan, C.O. Bellamy, D.R. Dunbar, D.J. Harrison, S. Prost, Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest. BMC Cancer 7, 215 (2007)
6. L.L. Seville, N. Shah, A.D. Westwell, W.C. Chan, Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. Curr Cancer Drug Targets 5, 159-170 (2005)
7. S. Paternot, T. Arsenijevic, K. Coulonval, L. Bockstaele, J.E. Dumont, P.P. Roger, Distinct specificities of pRb phosphorylation by CDK4 activated by cyclin D1 or cyclin D3: differential involvement in the distinct mitogenic modes of thyroid epithelial cells. Cell Cycle 5, 61-70 (2006)
8. S. Mani, C. Wang, K. Wu, R. Francis, R. Pestell, Cyclin-dependent kinase inhibitors: novel anticancer agents. Expert Opin Investig Drugs 9, 1849-1870 (2000)
9. L.E. Horton, D.J. Templeton, The cyclin box and C-terminus of cyclins A and E specify CDK activation and substrate specificity. Oncogene 14, 491-498 (1997)
10. A. Contreras, T.K. Hale, D.L. Stenoien, J.M. Rosen, M.A. Mancini, R.E. Herrera, The dynamic mobility of histone H1 is regulated by cyclin/CDK phosphorylation. Mol. Cell. Biol. 23, 8626-8636 (2003)
11. R.E. Herrera, F. Chen, R.A. Weinberg, Increased histone H1 phosphorylation and relaxed chromatin structure in Rb-deficient fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 93, 11510-11515 (1996)
12. D. Donjerkovic, D.W. Scott, Regulation of the G1 phase of the mammalian cell cycle. Cell Res 10, 1-16 (2000)
13. G.W. Woodfield, A.D. Horan, Y. Chen, R.J. Weigel, TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res. 67, 8439-8443 (2007)
14. A. Fritah, C. Saucier, J. Mester, G. Redeuilh, M. Sabbah, p21WAF1/CIP1 selectively controls the transcriptional activity of estrogen receptor alpha. Mol. Cell. Biol. 25, 2419-2430 (2005)
15. Y. Ye, H. Yang, H.B. Grossman, C. Dinney, X. Wu, J. Gu, Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 112, 2467-2474 (2008)
16. P.B. Burton, C.J. Anderson, C.M. Corbishly, Caspase 3 and p27 as predictors of invasive bladder cancer. N. Engl. J. Med. 343, 1418-1420 (2000)
17. S. Goenka, J. Youn, L.M. Dzurek, U. Schindler, L.-Y. Yu-Lee, M. Boothby, Paired Stat6 C-terminal transcription activation domains required both for inhibition of an IFN-responsive promoter and trans-activation. J. Immunol. 163, 4663-4672 (1999)
18. J.L. Gooch, B. Christy, D. Yee, STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells. Neoplasia 4, 324-331 (2002)
19. B. Borud, T. Hoang, M. Bakke, A.L. Jacob, J. Lund, G. Mellgren, The nuclear receptor coactivators p300/CBP/cointegrator-associated protein (p/CIP) and transcription intermediary factor 2 (TIF2) differentially regulate PKA-stimulated transcriptional activity of steroidogenic factor 1. Mol. Endocrinol. 16, 757-773 (2002)
20. N.A. Hanley, S.G. Ball, M. Clement-Jones, D.M. Hagan, T. Strachan, S. Lindsay, S. Robson, H. Ostrer, K.L. Parker, D.I. Wilson, Expression of steroidogenic factor 1 and Wilms' tumour 1 during early human gonadal development and sex determination. Mech. Dev. 87, 175-180 (1999)
21. S. Minami, N. Ohtani-Fujita, E. Igata, T. Tamaki, T. Sakai, Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Lett. 411, 1-6 (1997)
22. M. Wei, B. Liu, L. Su, J. Li, J. Zhang, Y. Yu, M. Yan, Z. Yang, X. Chen, J. Liu, X. Lv, H. Nie, Q. Zhang, Z. Zheng, B. Yu, J. Ji, Z. Zhu, Q. Gu, A novel plant homeodomain finger 10-mediated antiapoptotic mechanism involving repression of caspase-3 in gastric cancer cells. Mol. Cancer Ther. 9, 1764-1774 (2010)
23. Y. Qu, J.F. Li, Q. Cai, Y.W. Wang, Q.L. Gu, Z.G. Zhu, B.Y. Liu, Over-expression of FRZB in gastric cancer cell suppresses proliferation and induces differentiation. J. Cancer Res. Clin. Oncol. 134, 353-364 (2008)
24. D. Wei, M. Kanai, Z. Jia, X. Le, K. Xie, Kruppel-like factor 4 induces p27Kip1 expression in and suppresses the growth and metastasis of human pancreatic cancer cells. Cancer Res. 68, 4631-4639 (2008)
25. E. di Martino, C.G. L'Hote, W. Kennedy, D.C. Tomlinson, M.A. Knowles, Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene 28, 4306-4316 (2009)
26. A. Freund, C. Chauveau, J.P. Brouillet, A. Lucas, M. Lacroix, A. Licznar, F. Vignon, G. Lazennec, IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 22, 256-265 (2003)
27. M. Wei, Z. Wang, H. Yao, Z. Yang, Q. Zhang, B. Liu, Y. Yu, L. Su, Z. Zhu, Q. Gu, P27(Kip1), regulated by glycogen synthase kinase-3beta, results in HMBA-induced differentiation of human gastric cancer cells. BMC Cancer 11, 109-121 (2011)
28. M. Belyavskyi, S.C. Braunagel, M.D. Summers, The structural protein ODV-EC27 of Autographa californica nucleopolyhedrovirus is a multifunctional viral cyclin. Proc. Natl. Acad. Sci. U. S. A. 95, 11205-11210 (1998)
29. P.C. Hsieh, J.C. Chang, W.T. Sun, S.C. Hsieh, M.C. Wang, F.F. Wang, p53 downstream target DDA3 is a novel microtubule-associated protein that interacts with end-binding protein EB3 and activates beta-catenin pathway. Oncogene 26, 4928-4940 (2007)
30. M.L. Whitfield, G. Sherlock, A.J. Saldanha, J.I. Murray, C.A. Ball, K.E. Alexander, J.C. Matese, C.M. Perou, M.M. Hurt, P.O. Brown, D. Botstein, Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell. 13, 1977-2000 (2002)
31. E.A. Musgrove, B. Sarcevic, R.L. Sutherland, Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation. J. Cell. Biochem. 60, 363-378 (1996)
32. M. Kitagawa, H. Higashi, I.S. Takahashi, T. Okabe, H. Ogino, Y. Taya, S. Hishimura, A. Okuyama, A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. Oncogene 9, 2549-2557 (1994)
33. E.S. Child, D.J. Mann, Novel properties of the cyclin encoded by Human Herpesvirus 8 that facilitate exit from quiescence. Oncogene 20, 3311-3322 (2001)
34. L. Arpa, A.F. Valledor, J. Lloberas, A. Celada, IL-4 blocks M-CSF-dependent macrophage proliferation by inducing p21Waf1 in a STAT6-dependent way. Eur. J. Immunol. 39, 514-526 (2009)
35. B. Cen, A. Deguchi, I.B. Weinstein, Activation of protein kinase G Increases the expression of p21CIP1, p27KIP1, and histidine triad protein 1 through Sp1. Cancer Res. 68, 5355-5362 (2008)
36. S. Lu, G. Jenster, D.E. Epner, Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol. Endocrinol. 14, 753-760 (2000)
37. T.H. Lee, H.C. Chang, L.Y. Chuang, W.C. Hung, Involvement of PKA and Sp1 in the induction of p27(Kip1) by tamoxifen. Biochem. Pharmacol. 66, 371-377 (2003)
38. S. Ryhanen, T. Jaaskelainen, A. Mahonen, P.H. Maenpaa, Inhibition of MG-63 cell cycle progression by synthetic vitamin D3 analogs mediated by p27, Cdk2, cyclin E, and the retinoblastoma protein. Biochem. Pharmacol. 66, 495-504 (2003)
39. K. Okamoto, Y. Okamoto, T. Kawakubo, J. Iwata, Y. Yasuda, T. Tsukuba, K. Yamamoto, Role of the transcription factor Sp1 in regulating the expression of the murine cathepsin E gene. J. Biochem. 151, 263-272 (2012)
40. A.M. Stutz, L.A. Pickart, A. Trifilieff, T. Baumruker, E. Prieschl-Strassmayr, M. Woisetschlager, The Th2 cell cytokines IL-4 and IL-13 regulate found in inflammatory zone 1/resistin-like molecule alpha gene expression by a STAT6 and CCAAT/enhancer-binding protein-dependent mechanism. J. Immunol. 170, 1789-1796 (2003)
41. V.T. Nguyen, E.N. Benveniste, Involvement of STAT-1 and ets family members in interferon-gamma induction of CD40 transcription in microglia/macrophages. J. Biol. Chem. 275, 23674-23684 (2000)
42. J. Fukuzawa, G.W. Booz, R.A. Hunt, N. Shimizu, V. Karoor, K.M. Baker, D.E. Dostal, Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3: an autocrine loop for hypertrophy. Hypertension 35, 1191-1196 (2000)
43. K. Barbulescu, C. Becker, J.F. Schlaak, E. Schmitt, K.H. Meyer zum Buschenfelde, M.F. Neurath, IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. J. Immunol. 160, 3642-3647 (1998)
44. H.J. Park, Y.S. Choi, C.E. Lee, Identification and activation mechanism of the interleukin-4-induced nuclear factor binding to the CD23(b) promoter in human B lymphocytes. Mol Cells 7, 755-761 (1997)
45. S. Asonuma, A. Imatani, N. Asano, T. Oikawa, H. Konishi, K. Iijima, T. Koike, S. Ohara, T. Shimosegawa, Helicobacter pylori induces gastric mucosal intestinal metaplasia through the inhibition of interleukin-4-mediated HMG box protein Sox2 expression. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G312-322 (2009)
46. M. Zhang, Y. Zhou, C. Xie, F. Zhou, Y. Chen, G. Han, W.J. Zhang, STAT6 specific shRNA inhibits proliferation and induces apoptosis in colon cancer HT-29 cells. Cancer Lett. 243, 38-46 (2006)
47. X.W. Zhang, Y.P. Sheng, Q. Li, W. Qin, Y.W. Lu, Y.F. Cheng, B.Y. Liu, F.C. Zhang, J. Li, G.P. Dimri, W.J. Guo, BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Mol. Cancer 9, 40-52 (2010)
48. J.P. Wiebe, M.J. Lewis, Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells. BMC Cancer 3, 9 (2003)
49. E.A. Musgrove, L.J. Hunter, C.S. Lee, A. Swarbrick, R. Hui, R.L. Sutherland, Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2. J. Biol. Chem. 276, 47675-47683 (2001)
50. R. Hui, G.L. Finney, J.S. Carroll, C.S. Lee, E.A. Musgrove, R.L. Sutherland, Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res. 62, 6916-6923 (2002)
51. C.R. Yu, R.M. Mahdi, S. Ebong, B.P. Vistica, J. Chen, Y. Guo, I. Gery, C.E. Egwuagu, Cell proliferation and STAT6 pathways are negatively regulated in T cells by STAT1 and suppressors of cytokine signaling. J. Immunol. 173, 737-746 (2004)
52. W. Reed, V.A. Flørenes, R. Holm, E. Hannisdal, J.M. Nesland, Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. 116-124 (1999)
53. S. Vanzulli, A. Efeyan, F. Benavides, L.A. Helguero, G. Peters, J. Shen, C.J. Conti, C. Lanari, A. Molinolo, p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas. Carcinogenesis 23, 749-758 (2002)
54. S.D. Groshong, G.I. Owen, B. Grimison, I.E. Schauer, M.C. Todd, T.A. Langan, R.A. Sclafani, C.A. Lange, K.B. Horwitz, Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27Kip1. Mol. Endocrinol. 11, 1593-1607 (1997)
55. M.H. Kaplan, C. Daniel, U. Schindler, M.J. Grusby, Stat proteins control lymphocyte proliferation by regulating p27Kip1 expression. Mol. Cell. Biol. 18, 1996-2003 (1998)
56. J. Liu, M.L. Estes, J.A. Drazba, H. Liu, R. Prayson, S. Kondo, B.S. Jacobs, G.H. Barnett, B.P. Barna, Anti-sense oligonucleotide of p21(waf1/cip1) prevents interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells. Oncogene 19, 661-669 (2000)
57. B.K. Patel, C.L. Keck, R.S. O'Leary, N.C. Popescu, W.J. LaRochelle, Localization of the human stat6 gene to chromosome 12q13.3-q14.1, a region implicated in multiple solid tumors. Genomics 52, 192-200 (1998)
58. A. Parcellier, M. Brunet, E. Schmitt, E. Col, C. Didelot, A. Hammann, K. Nakayama, K.I. Nakayama, S. Khochbin, E. Solary, C. Garrido, HSP27 favors ubiquitination and proteasomal degradation of p27Kip1 and helps S-phase re-entry in stressed cells. FASEB J. 20, 1179-1181 (2006)
59. Q. Zhang, L. Tian, A. Mansouri, A.L. Korapati, T.J. Johnson, F.X. Claret, Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells. FEBS Lett. 579, 3932-3940 (2005)
60. X. Wang, X. Liu, J. Fang, Y. Lu, J. He, X. Yao, Z. Yao, J. Yang, Coactivator P100 protein enhances STAT6-dependent transcriptional activation but has no effect on STAT1-mediated gene transcription. Anat Rec (Hoboken) 293, 1010-1016 (2010)
61. Y.L. Chai, J. Cui, N. Shao, E. Shyam, P. Reddy, V.N. Rao, The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. Oncogene 18, 263-268 (1999)
62. J. Yang, S. Aittomaki, M. Pesu, K. Carter, J. Saarinen, N. Kalkkinen, E. Kieff, O. Silvennoinen, Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II. EMBO J. 21, 4950-4958 (2002)
63. Z. Ai, W. Lu, S. Ton, H. Liu, T. Sou, Z. Shen, X. Qin, Arsenic trioxide-mediated growth inhibition in gallbladder carcinoma cells via down-regulation of Cyclin D1 transcription mediated by Sp1 transcription factor. Biochem. Biophys. Res. Commun. 360, 684-689 (2007)
64. Y. Chai, H.J. Lee, A.A. Shaik, K. Nkhata, C. Xing, J. Zhang, S.J. Jeong, S.H. Kim, J. Lu, Penta-O-galloyl-beta-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of cyclin-dependent kinase inhibitor 1A, cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple negative xenograft growth. Breast Cancer Res. 12, R67 (2012)
65. H.B. Nair, N.B. Kirma, M. Ganapathy, R.K. Vadlamudi, R.R. Tekmal, Estrogen receptor-beta activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy. Steroids 76, 792-796 (2011)
66. A. Shatnawi, T. Tran, M. Ratnam, R5020 and RU486 act as progesterone receptor agonists to enhance Sp1/Sp4-dependent gene transcription by an indirect mechanism. Mol. Endocrinol. 21, 635-650 (2007)
67. M. Wei, L. Zhu, Y. Li, W. Chen, B. Han, Z. Wang, J. He, H. Yao, Z. Yang, Q. Zhang, B. Liu, Q. Gu, Z. Zhu, K. Shen, Knocking down cyclin D1b inhibits breast cancer cell growth and suppresses tumor development in a breast cancer model. Cancer Sci. 102, 1537-1544 (2011)
68. N. Heldring, G.D. Isaacs, A.G. Diehl, M. Sun, E. Cheung, J.A. Ranish, W.L. Kraus, Multiple sequence-specific DNA-binding proteins mediate estrogen receptor signaling through a tethering pathway. Mol. Endocrinol. 25, 564-574 (2011)
69. W.J. Zhang, B.H. Li, X.Z. Yang, P.D. Li, Q. Yuan, X.H. Liu, S.B. Xu, Y. Zhang, J. Yuan, G.S. Gerhard, K.K. Masker, C. Dong, W.A. Koltun, M.J. Chorney, IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells. Cytokine 42, 39-47 (2008)
70. C. McDonald, N.C. Reich, Cooperation of the transcriptional coactivators CBP and p300 with Stat6. J. Interferon Cytokine Res. 19, 711-722 (1999)